Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech.
It is a $631B healthcare company. Revenue grew 8.1% over the last year, it keeps 21¢ of every dollar of sales as profit, and its net debt equals ~1.3 years of free cash flow. It trades at 29.9× earnings — in the most expensive third of its own history.
- Website
- jnj.com
- Location
- New Brunswick, NJ
- Employees
- 140 800
- Sector
- Healthcare
- Founded
- 1886
- Next earnings
- Oct 13, 2026 · tomorrow
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong profitability and moat; Valuation and Health lag behind.
Valuation36
- P/E vs own history84th pct · 0/25
- FCF yield3.5% · 12/25
- P/S6.4x · 12/25
- EV/EBITDA20.4x · 12/25
Growth63
- Revenue CAGR0.1% · 6/25
- Net income CAGR6.4% · 12/25
- EPS CAGR ~5Y14.9% · 20/25
- Fwd implied growth36.3% · 25/25
Profitability95
- ROIC24.5% · 20/25
- ROE25.7% · 25/25
- Net margin21.5% · 25/25
- Operating margin25.7% · 25/25
Health49
- Altman Zn/a · 0/25
- Current ratio1.09 · 12/25
- Interest coverage34.0x · 25/25
- Net cash / debtD/A 14% · 12/25
Quality72
- Piotroski F5/9 · 15/25
- Beneish M-2.40 · 20/25
- FCF conversion106% · 25/25
- Margin stabilityσ 9.9% · 12/25
Moat87
- ROIC >12% years10/10 yrs · 25/25
- Median gross margin67.6% · 25/25
- FCF-positive years10/10 yrs · 25/25
- Worst-year net marginworst 1.7% · 12/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- FY2023FinancialBest year on record$35.2B net income
- May 4, 2023MilestoneSpun off Kenvueconsumer brands (Tylenol, Band-Aid) become a separate company
- 2017AcquisitionJohnson & Johnson acquired Actelion in a $30 billion deal, the largest ever purchase by the company
- FY2016FinancialProfitable every year on record10 consecutive profitable years in our data
- FY2016FinancialRevenue already above $50B$71.9B in first reported year
- FY2016FinancialPositive free cash flow every year since10-year streak
- 2008AcquisitionThe company acquired HealthMedia, later renamed to Health & Wellness Solutions and the Human…
- 1998AcquisitionDePuy was acquired by Johnson & Johnson in 1998 for $3.5 billion
- 1987MilestoneAcuvue contact lenses became the first disposable contact lenses available to consumers
- 1982MilestoneTylenol recallgold-standard crisis response — pulled 31M bottles
- Sep 24, 1944IPOIPO on NYSEfamily company goes public
- 1931ProductJohnson & Johnson introduced the first prescription contraceptive gel marketed as Ortho-Gynol
- 1920ProductBand-Aida cotton buyer's invention for his accident-prone wife
- 1894ProductThe company introduced the world's first maternity kit in 1894 to aid at-home births, called Dr
- 1886FoundedFounded in New Brunswickthe Johnson brothers — sterile surgical dressings
- 1886ProductRobert Wood Johnson joined his brothers, James Wood Johnson and Edward Mead Johnson
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (68.0%)
- Strongly profitable — 21.5% net margin
- Strong cash conversion — FCF is 22.7% of revenue
- Interest covered 34.0× by operating earnings
- High returns on invested capital (ROIC 24.5%)
Watch-outs
Nothing stands out as a concern in the available data.
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+8.1% YoY
- Profitable — makes more than it spends$21.0B TTM
- Profit growing — earnings are higher than last year+17.9% YoY
- Generates cash — cash left after running and investing$22.2B TTM
- Debt under control — could handle its obligations~1.3y of cash flow to repay
- Established company — not a micro-cap — lower blow-up risk$631B market cap
- Not printing shares — share count not ballooning — you keep your slice-9.0% shares over ~5y
- Proven track record — years of profitability behind it10/10 profitable years
- Financially stable — balance sheet not near distresshealth score 37/100
- Pays a dividend — returns cash to shareholdersyield 2.00%
- Valuation not extreme — price not wildly above earningsP/E 29.9
Peer comparisonJohnson & Johnson vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| JNJ this company | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
| AZN AstraZeneca PLC | $246.9B | 23.4 | +8.6% | 17.4% | Solid |
Head-to-head: JNJ vs LLY · JNJ vs ABBV · JNJ vs MRK
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/JNJ
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of JNJ on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $261.79 · market cap $631B.